

Dive Into Patients' COVID-19 Experience

Ask the right questions and gather patient insights to better inform treatment decisions with the IQVIA COVID-19 Daily Diary and Weekly Diary Item Banks

The world is rapidly evolving in swift response to the ongoing challenges of the COVID-19 pandemic. The healthcare industry is making huge efforts to improve our understanding of COVID-19 and investigate potential treatments and vaccines. Sponsors need scientifically sound data collection tools to support COVID-19 related studies, while also gaining a deep understanding of the patient experience.

Generate important COVID-19 patient insights for your study

To address this, we've developed the IQVIA COVID-19

Daily Diary (ICDD) Item Bank® and the IQVIA COVID-19

Weekly Diary (ICWD) Item Bank®. These item banks
measure both short-term and long-term symptoms,
patient experiences, and associated impacts of COVID-19
infection and the pandemic more broadly in treatment,
vaccine, and epidemiological trials — ultimately helping
to bring safe and effective treatments to market faster
while prioritizing patient outcomes.



Leverages COVID-19 patient input to support product labeling in accordance with FDA Guidance for Industry Patient-Reported Outcome (PRO) Measures

Addresses a variety of research needs with **customizable daily and weekly item banks**

Key customer benefits

Ta.



Offers the opportunity to differentiate your product by including PROs in a COVID-19 study setting in line with FDA COVID-19 Treatment or Prevention Guidance for Industry

Provides holistic understanding of the patient experience with COVID-19 in epidemiological studies

Assesses incidence and severity of both acute and chronic/long-term symptomology

Evaluates patient-reported efficacy of COVID-19 treatments
and vaccines in clinical trials

Key features Content valid item banks (developed through literature review, 5. Have you had the following in the past week? Please select any social media listening, and patient interviews) symptoms you may have experienced Items arranged in **seven groups** that can be individually selected ☐ Wet cough based on research needs (as shown in Table 1) ☐ Dry cough Phlegm / mucus come up when you Measure up to 55 different signs & symptoms experienced by patients, along with additional items assessing impacts ☐ Chest congestion caused by the COVID-19 pandemic Chest tightness Capture symptom frequency (including onset for vaccine studies) ☐ Shortness of breath and symptom severity Available in both one-day (ICDD) and one-week (ICWD) recall periods Back Next Available for immediate electronic implementation on various devices through the IQVIA eCOA platform library of assessments

Table 1. Available item banks

	GROUP A	GROUP B	GROUP C	GROUP D	GROUP E	GROUP F	GROUP G
SYMPTOM OR IMPACTS	Fever	Prevalence and severity of symptoms*	Loneliness and detachment	Physical function	Work and productivity	Worry	General pandemic impacts
NUMBER OF ITEMS	2	108	6	6	11	3	7

^{*2} items (incidence and severity) for each of 55 symptoms. It is not required to measure all symptoms; symptoms can be selected based on your research needs

IQVIA is committed to helping you address COVID-19 challenges so you can keep moving forward, capture the patient experience and confidently achieve your study goals. Contact our experts today to find out how we can support you.

Licensing

IQVIA holds the copyright for the ICDD and ICWD. Any user of the ICDD or ICWD must obtain permission for use from IQVIA.

